Brain Tumours

Trial design

Author Division Olaf Witt SIOP LGG 201X

Strategisches Konzept

PAge69 1/25/2016 | a

2

Primary objectives: => PFS & CNS & visual function => biomarker driven prediction of overall course of disease Secondary objectives: => PA, DG2, infants, other LGGs => outcome in molecular subgroups => neuro-psychology, endocrinology, diencephalic syndrome, neurotox+pharmacogenomics

2

MEKi

under discussion: • Introduce MEKi now • skip 12 vs 18 months randomization • keep adaptive design